Having originated the first approved gene therapy in 2012, uniQure is a leading pioneer in the field. By leveraging their modular and validated technology platform, uniQure is rapidly advancing a pipeline of AAV-based gene therapies to treat patients with hemophilia, Huntington’s disease, and other severe genetic diseases.
Number of employees: 250 – 1000
Location: Amsterdam, Netherlands
Bring a gene therapy pioneer from paper to the cloud.
Difficulty tracking experiments with paper documentation
Paper-based workflows made it difficult to track results and streamline experiment execution.
Sharing data and collaborating across international sites
As an international company with worksites in Amsterdam and Lexington, MA, uniQure found it challenging to share data and collaborate across research sites.
Difficulty assessing experiment quality
A lack of standardized Notebook templates led to nonstandard experimental workflows and impeded quality control.